Brenipatide clinical trials
Also written LY3537031.
How each study uses brenipatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the brenipatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2026 (9)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 8 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test brenipatide.
- Nov 2026A Study of LY3537031 in Overweight, Obese, and Healthy ParticipantsPhase 1 · Eli Lilly and Company
- Nov 2026A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentPhase 1 · Eli Lilly and Company
- Feb 2027A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityPhase 1 · Eli Lilly and Company
- Feb 2027A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid RelapsePhase 2 · Eli Lilly and Company
- Jul 2027A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)Phase 2 · Eli Lilly and Company
- Sep 2027A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)Phase 2 · Eli Lilly and Company
- Nov 2027A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)Phase 2 · Eli Lilly and Company
- Nov 2027A Study of Brenipatide in Adult Participants With SchizophreniaPhase 2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses brenipatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- A Study of Brenipatide in Participants With Major Depressive DisorderNot yet recruitingPhase 2Eli Lilly and CompanyNCT07928245Written as Brenipatide
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)RecruitingPhase 2Eli Lilly and CompanyNCT07545772Written as LY3537031
- A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaRecruitingPhase 2Eli Lilly and CompanyNCT07219173Written as Brenipatide
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)RecruitingPhase 2Eli Lilly and CompanyNCT07759245Written as Brenipatide
- A Study of Brenipatide in Participants With Alcohol Use DisorderRecruitingPhase 3Eli Lilly and CompanyNCT07219953Written as LY3537031
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)RecruitingPhase 2Eli Lilly and CompanyNCT07545759Written as LY3537031
- A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)RecruitingPhase 2Eli Lilly and CompanyNCT07286175Written as Brenipatide
- A Study of Brenipatide in Participants With Opioid Use DisorderRecruitingPhase 2Eli Lilly and CompanyNCT07420283Written as Brenipatide
- A Study of Brenipatide in Adult Participants With Major Depressive DisorderRecruitingPhase 3Eli Lilly and CompanyNCT07412756Written as Brenipatide
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderRecruitingPhase 3Eli Lilly and CompanyNCT07775300Written as Brenipatide
- A Study of Brenipatide in Adult Participants With SchizophreniaRecruitingPhase 2Eli Lilly and CompanyNCT07410507Written as Brenipatide
- A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderRecruitingPhase 3Eli Lilly and CompanyNCT07219966Written as LY3537031
- A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentRecruitingPhase 1Eli Lilly and CompanyNCT07165002Written as LY3537031
- A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid RelapseRecruitingPhase 2Eli Lilly and CompanyNCT07223840Written as Brenipatide
- A Study of LY3537031 in Overweight, Obese, and Healthy ParticipantsActive, not recruitingPhase 1Eli Lilly and CompanyNCT06606106Written as LY3537031
- A Study of How the Body Absorbs LY3537031CompletedPhase 1Eli Lilly and CompanyNCT07202871Written as LY3537031
- A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityActive, not recruitingPhase 1Eli Lilly and CompanyNCT07476118Written as Brenipatide
- A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal ImpairmentCompletedPhase 1Eli Lilly and CompanyNCT07165015Written as LY3537031
- A Study of LY3537031 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04648865Written as LY3537031
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- A Study of Brenipatide in Participants With Major Depressive DisorderNov 10, 2026NCT07928245
Codes
What other systems call brenipatide · ClinicalTrials.gg INT016163
- UNII (FDA) C3939LZT6JBRENIPATIDEOne source FDA
- NCI Thesaurus C223275BrenipatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C3939LZT6J | BRENIPATIDE | One source FDA |
| NCI Thesaurus | C223275 | Brenipatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.